

SS&C Technologies Holdings, Inc. and Subsidiaries
Condensed Consolidated Statements of Comprehensive Income
(in millions, except per share data)
(unaudited)

	Three Months Ended June 30,		Six Months Ended June 30,	
	2026	2025	2026	2025
Revenues:				
Technology-enabled services	\$ 1,408.2	\$ 1,267.7	\$ 2,815.5	\$ 2,537.6
License, maintenance and related	287.5	269.1	527.3	513.1
Total revenues	1,695.7	1,536.8	3,342.8	3,050.7
Cost of revenues:				
Technology-enabled services	771.6	693.9	1,512.1	1,361.2
License, maintenance and related	105.8	106.0	210.6	205.5
Total cost of revenues	877.4	799.9	1,722.7	1,566.7
Gross profit	818.3	736.9	1,620.1	1,484.0
Operating expenses:				
Selling and marketing	160.5	152.4	312.2	304.7
Research and development	132.3	128.1	266.9	257.2
General and administrative	108.4	111.9	225.7	219.7
Total operating expenses	401.2	392.4	804.8	781.6
Operating income	417.1	344.5	815.3	702.4
Interest expense, net	(107.0)	(105.5)	(212.4)	(210.7)
Other income (expense), net	1.1	(1.1)	7.9	6.1
Equity in earnings of unconsolidated affiliates, net	3.0	1.6	6.9	3.9
Loss on extinguishment of debt	—	—	(0.4)	(0.9)
Income before income taxes	314.2	239.5	617.3	500.8
Provision for income taxes	78.9	58.4	155.7	106.5
Net income	235.3	181.1	461.6	394.3
Net income attributable to noncontrolling interest	(0.5)	(0.3)	(0.7)	(0.5)
Net income attributable to SS&C common stockholders	\$ 234.8	\$ 180.8	\$ 460.9	\$ 393.8
Basic earnings per share attributable to SS&C common stockholders	\$ 0.99	\$ 0.74	\$ 1.92	\$ 1.60
Diluted earnings per share attributable to SS&C common stockholders	\$ 0.97	\$ 0.72	\$ 1.88	\$ 1.55
Basic weighted-average number of common shares outstanding	238.1	244.9	239.8	245.4
Diluted weighted-average number of common and common equivalent shares outstanding	242.0	252.2	244.6	253.5
Net income	\$ 235.3	\$ 181.1	\$ 461.6	\$ 394.3
Other comprehensive (loss) income, net of tax:				
Foreign currency exchange translation adjustment	(2.6)	207.8	(74.7)	300.3
Change in defined benefit pension obligation	(0.2)	—	0.2	—
Total other comprehensive (loss) income, net of tax	(2.8)	207.8	(74.5)	300.3
Comprehensive income	232.5	388.9	387.1	694.6
Comprehensive income attributable to noncontrolling interest	(0.5)	(0.3)	(0.7)	(0.5)
Comprehensive income attributable to SS&C common stockholders	\$ 232.0	\$ 388.6	\$ 386.4	\$ 694.1

SS&C Technologies Holdings, Inc. and Subsidiaries
Condensed Consolidated Balance Sheets
(in millions)
(unaudited)

	June 30, 2026	December 31, 2025
Assets		
Current assets:		
Cash and cash equivalents	\$ 434.8	\$ 462.1
Funds receivable and funds held on behalf of clients	3,984.5	3,799.5
Accounts receivable, net	1,023.6	978.7
Contract asset	41.0	49.2
Prepaid expenses and other current assets	213.4	193.7
Restricted cash	2.3	4.5
Total current assets	5,699.6	5,487.7
Property, plant and equipment, net	265.3	289.5
Operating lease right-of-use assets	214.6	233.3
Investments	174.6	174.4
Unconsolidated affiliates	295.3	307.7
Contract asset	155.4	133.1
Goodwill	9,930.0	9,991.3
Intangible and other assets, net	3,873.8	4,094.7
Total assets	\$ 20,608.6	\$ 20,711.7
Liabilities and Equity		
Current liabilities:		
Current portion of long-term debt	\$ 265.0	\$ 25.0
Client funds obligations	3,984.5	3,799.5
Accounts payable	62.6	87.2
Income taxes payable	—	23.3
Accrued employee compensation and benefits	233.5	348.9
Interest payable	32.1	31.6
Other accrued expenses	290.1	303.4
Deferred revenue	486.4	492.4
Total current liabilities	5,354.2	5,111.3
Long-term debt, net of current portion	7,312.2	7,408.4
Operating lease liabilities	200.1	213.2
Other long-term liabilities	193.8	190.2
Deferred income taxes	837.8	846.8
Total liabilities	13,898.1	13,769.9
SS&C stockholders' equity	6,640.7	6,887.6
Noncontrolling interest	69.8	54.2
Total equity	6,710.5	6,941.8
Total liabilities and equity	\$ 20,608.6	\$ 20,711.7

SS&C Technologies Holdings, Inc. and Subsidiaries
Condensed Consolidated Statements of Cash Flows
(in millions)
(unaudited)

	Six Months Ended June 30,	
	2026	2025
Cash flow from operating activities:		
Net income	\$ 461.6	\$ 394.3
Adjustments to reconcile net income to net cash provided by operating activities:		
Depreciation and amortization	361.9	345.7
Equity in earnings of unconsolidated affiliates, net	(6.9)	(3.9)
Distributions received from unconsolidated affiliates	16.9	—
Stock-based compensation expense	123.7	112.9
Unrealized net (gains) losses on investments	(1.2)	3.5
Amortization of debt financing costs	3.7	3.3
Loss on extinguishment of debt	0.4	0.9
Loss on sale or disposition of property and equipment	2.9	0.1
Deferred income taxes	(7.1)	(41.8)
Provision for credit losses	11.6	9.2
Changes in operating assets and liabilities, excluding effects from acquisitions:		
Accounts receivable	(59.3)	(27.8)
Prepaid expenses and other assets	(32.5)	(35.5)
Contract assets	(13.8)	(24.3)
Accounts payable	(25.8)	(14.8)
Accrued expenses and other liabilities	(113.2)	(19.6)
Income taxes prepaid and payable	2.1	(35.2)
Deferred revenue	(8.6)	(21.9)
Net cash provided by operating activities	716.4	645.1
Cash flow from investing activities:		
Business acquisitions, net of cash acquired	(0.2)	(5.8)
Additions to property and equipment	(19.3)	(35.6)
Proceeds from sale of property and equipment	2.1	—
Additions to capitalized software	(125.9)	(99.8)
Investments in securities	(7.5)	(2.5)
Proceeds from sales / maturities of investments	7.7	0.1
Distributions received from (contributions to) unconsolidated affiliates	2.8	(9.8)
Collection of other non-current receivables	5.3	5.3
Net cash used in investing activities	(135.0)	(148.1)
Cash flow from financing activities:		
Cash received from debt borrowings	450.0	122.0
Repayments of debt	(310.0)	(312.0)
Net decrease in client funds obligations	(132.1)	(391.2)
Proceeds from exercise of stock options	31.9	240.5
Withholding taxes paid related to equity award net share settlement	(55.8)	(47.4)
Purchases of common stock for treasury	(605.7)	(477.2)
Dividends paid on common stock	(129.3)	(122.5)
Proceeds from noncontrolling interests	14.9	—
Net cash used in financing activities	(736.1)	(987.8)
Effect of exchange rate changes on cash, cash equivalents and restricted cash	(6.9)	11.7
Net decrease in cash, cash equivalents and restricted cash	(161.6)	(479.1)
Cash, cash equivalents and restricted cash and cash equivalents, beginning of period	3,573.8	3,370.5
Cash, cash equivalents and restricted cash and cash equivalents, end of period	\$ 3,412.2	\$ 2,891.4
Reconciliation of cash, cash equivalents and restricted cash and cash equivalents:		
Cash and cash equivalents	\$ 434.8	\$ 480.3
Restricted cash and cash equivalents	2.3	2.6
Restricted cash and cash equivalents included in funds receivable and funds held on behalf of clients	2,975.1	2,408.5
	\$ 3,412.2	\$ 2,891.4

SS&C Technologies Holdings, Inc. and Subsidiaries
Disclosures Relating to Non-GAAP Financial Measures

Note 1. Reconciliation of Revenues to Adjusted Revenues

Adjusted revenues represents revenues adjusted to include a) amounts that would have been recognized if deferred revenue were not adjusted to fair value at the date of acquisition and b) amounts that would have been recognized if not for adjustments to deferred revenue and retained earnings related to the adoption of ASC 606. Adjusted revenues is presented because we use this measure to evaluate performance of our business against prior periods and believe it is a useful indicator of the underlying performance of our business. Adjusted revenues is not a recognized term under generally accepted accounting principles (“GAAP”). Adjusted revenues does not represent revenues, as that term is defined under GAAP, and should not be considered as an alternative to revenues as an indicator of our operating performance. Adjusted revenues as presented herein is not necessarily comparable to similarly titled measures presented by other companies. Below is a reconciliation of adjusted revenues to revenues, the GAAP measure we believe to be most directly comparable to adjusted revenues.

(in millions)	Three Months Ended June 30,		Six Months Ended June 30,	
	2026	2025	2026	2025
Revenues	\$ 1,695.7	\$ 1,536.8	\$ 3,342.8	\$ 3,050.7
Purchase accounting adjustments impact on revenue	1.2	1.0	2.3	1.9
Adjusted revenues	\$ 1,696.9	\$ 1,537.8	\$ 3,345.1	\$ 3,052.6

The following is a breakdown of technology-enabled services and license, maintenance and related revenues and adjusted technology-enabled services and license, maintenance and related revenues.

(in millions)	Three Months Ended June 30,		Six Months Ended June 30,	
	2026	2025	2026	2025
Technology-enabled services	\$ 1,408.2	\$ 1,267.7	\$ 2,815.5	\$ 2,537.6
License, maintenance and related	287.5	269.1	527.3	513.1
Total revenues	\$ 1,695.7	\$ 1,536.8	\$ 3,342.8	\$ 3,050.7
Technology-enabled services	\$ 1,409.4	\$ 1,268.7	\$ 2,817.8	\$ 2,539.5
License, maintenance and related	287.5	269.1	527.3	513.1
Total adjusted revenues	\$ 1,696.9	\$ 1,537.8	\$ 3,345.1	\$ 3,052.6

Note 2. Reconciliation of Operating Income to Adjusted Operating Income

Adjusted operating income represents operating income adjusted for amortization of intangible assets, stock-based compensation, purchase accounting adjustments for deferred revenue and related costs, ASC 606 adoption impact and other expenses. Adjusted operating income is presented because we use this measure to evaluate performance of our business and believe it is a useful indicator of our underlying performance. Adjusted operating income is not a recognized term under GAAP. Adjusted operating income does not represent operating income, as that term is defined under GAAP, and should not be considered as an alternative to operating income as an indicator of our operating performance. Adjusted operating income as presented herein is not necessarily comparable to similarly titled measures by other companies. The following is a reconciliation between adjusted operating income and operating income, the GAAP measure we believe to be most directly comparable to adjusted operating income.

(in millions)	Three Months Ended June 30,		Six Months Ended June 30,	
	2026	2025	2026	2025
Operating income	\$ 417.1	\$ 344.5	\$ 815.3	\$ 702.4
Amortization of intangible assets	163.3	157.0	326.2	310.0
Stock-based compensation	62.0	60.2	123.7	112.9
Acquisition related	0.6	1.7	1.5	3.0
Facilities and workforce restructuring	9.4	17.1	18.6	24.2
Other (1)	3.0	4.0	4.9	8.3
Adjusted operating income	\$ 655.4	\$ 584.5	\$ 1,290.2	\$ 1,160.8
Adjusted operating income attributable to noncontrolling interest (2)	(1.6)	(1.0)	(2.8)	(2.0)
Adjusted operating income attributable to SS&C common stockholders	\$ 653.8	\$ 583.5	\$ 1,287.4	\$ 1,158.8

- (1) Other includes additional expenses and income that are permitted to be excluded per the terms of our Credit Agreement from Consolidated EBITDA, a financial measure used in calculating our covenant compliance.
- (2) Adjusted operating income attributable to noncontrolling interest represents the proportionate share of adjusted operating income of DomaniRx, LLC (a consolidated joint venture) retained by our joint venture partners.

Note 3. Reconciliation of Net Income to EBITDA, Consolidated EBITDA and Adjusted Consolidated EBITDA

EBITDA represents net income before interest expense, income taxes, depreciation and amortization. Consolidated EBITDA, defined under our Credit Agreement entered into in April 2018, as amended, is used in calculating covenant compliance, and is EBITDA adjusted for certain items. Consolidated EBITDA is calculated by subtracting from or adding to EBITDA items of income or expense described below. Adjusted Consolidated EBITDA is calculated by subtracting acquired EBITDA (as defined below) from Consolidated EBITDA. EBITDA, Consolidated EBITDA and Adjusted Consolidated EBITDA are presented because we use these measures to evaluate performance of our business and believe them to be useful indicators of an entity's debt capacity and its ability to service debt. EBITDA, Consolidated EBITDA and Adjusted Consolidated EBITDA are not recognized terms under GAAP and should not be considered in isolation or as alternatives to operating income, net income or cash flows from operating activities as indicators of our operating performance. These measures are not necessarily comparable to similarly titled measures by other companies. The following is a reconciliation of EBITDA, Consolidated EBITDA and Adjusted Consolidated EBITDA to net income.

	Three Months Ended June 30,		Six Months Ended June 30,		Twelve Months Ended June 30,
(in millions)	2026	2025	2026	2025	2026
Net income	\$ 235.3	\$ 181.1	\$ 461.6	\$ 394.3	\$ 866.0
Interest expense, net	107.0	105.5	212.4	210.7	428.0
Provision for income taxes	78.9	58.4	155.7	106.5	225.4
Depreciation and amortization	180.9	174.9	361.9	345.7	720.0
EBITDA	602.1	519.9	1,191.6	1,057.2	2,239.4
Stock-based compensation	62.0	60.2	123.7	112.9	268.5
Acquired EBITDA and cost savings (1)	—	—	—	—	18.5
Equity in earnings of unconsolidated affiliates, net	(3.0)	(1.6)	(6.9)	(3.9)	6.4
Investment gains (2)	(2.8)	(0.9)	(11.5)	(10.2)	(15.4)
Facilities and workforce restructuring	9.4	17.1	18.6	24.2	39.5
Acquisition related	0.6	1.7	1.5	3.0	10.1
Other (3)	4.0	4.9	7.5	11.0	47.5
Consolidated EBITDA	\$ 672.3	\$ 601.3	\$ 1,324.5	\$ 1,194.2	\$ 2,614.5
Acquired EBITDA and cost savings (1)	—	—	—	—	(18.5)
Adjusted Consolidated EBITDA	\$ 672.3	\$ 601.3	\$ 1,324.5	\$ 1,194.2	\$ 2,596.0
Adjusted Consolidated EBITDA attributable to noncontrolling interest (4)	(1.6)	(0.9)	(2.8)	(1.9)	(4.1)
Adjusted Consolidated EBITDA attributable to SS&C common stockholders	\$ 670.7	\$ 600.4	\$ 1,321.7	\$ 1,192.3	\$ 2,591.9

- (1) Acquired EBITDA reflects the EBITDA impact of significant businesses that were acquired during the last twelve months as if the acquisition occurred at the beginning of the trailing twelve-month period, as well as cost savings enacted in connection with acquisitions.
- (2) Investment gains includes unrealized fair value adjustments of investments and dividend income received on investments.
- (3) Other includes additional expenses and income that are permitted to be excluded per the terms of our Credit Agreement from Consolidated EBITDA, a financial measure used in calculating our covenant compliance, and includes a loss on the sale of fixed assets of \$33.3 million during the twelve months ended June 30, 2026.
- (4) Adjusted Consolidated EBITDA attributable to noncontrolling interest represents the proportionate share of adjusted Consolidated EBITDA of DomaniRx, LLC (a consolidated joint venture) retained by our joint venture partners.

Note 4. Reconciliation of Net Income to Adjusted Net Income and Diluted Earnings Per Share Attributable to SS&C to Adjusted Diluted Earnings Per Share Attributable to SS&C

Adjusted net income and adjusted diluted earnings per share attributable to SS&C represent net income and earnings per share attributable to SS&C before amortization of intangible assets and deferred financing costs, stock-based compensation, purchase accounting adjustments and other items. We consider adjusted net income and adjusted diluted earnings per share attributable to SS&C to be important to management and investors because they represent our operational performance exclusive of the effects of amortization of intangible assets and deferred financing costs, stock-based compensation, purchase accounting adjustments, loss on extinguishment of debt and other items, that are not operational in nature or comparable to those of our competitors. Adjusted net income and adjusted diluted earnings per share are not recognized terms under GAAP. Adjusted net income and adjusted diluted earnings per share do not represent net income or diluted earnings per share, as those terms are defined under GAAP, and should not be considered as alternatives to net income or diluted earnings per share as indicators of our operating performance. Adjusted net income and adjusted diluted earnings per share attributable to SS&C as presented herein are not necessarily comparable to similarly titled measures presented by other companies. Below is a reconciliation of adjusted net income and adjusted diluted earnings per share attributable to SS&C to net income and diluted earnings per share attributable to SS&C, the GAAP measures we believe to be most directly comparable to adjusted net income and adjusted diluted earnings per share.

(in millions, except per share data)	Three Months Ended June 30,		Six Months Ended June 30,	
	2026	2025	2026	2025
GAAP – Net income	\$ 235.3	\$ 181.1	\$ 461.6	\$ 394.3
Amortization of intangible assets	163.3	157.0	326.2	310.0
Stock-based compensation	62.0	60.2	123.7	112.9
Equity in earnings of unconsolidated affiliates, net	(3.0)	(1.6)	(6.9)	(3.9)
Investment (gains) losses (1)	(1.8)	1.7	(1.3)	3.5
Facilities and workforce restructuring	9.4	17.1	18.6	24.2
Acquisition related	0.6	1.7	1.5	3.0
Other (2)	6.5	7.8	12.6	16.7
Income tax effect (3)	(45.1)	(48.0)	(89.9)	(106.3)
Adjusted net income	\$ 427.2	\$ 377.0	\$ 846.1	\$ 754.4
Adjusted net income attributable to noncontrolling interest (4)	(1.6)	(1.4)	(2.8)	(2.7)
Adjusted net income attributable to SS&C common stockholders	\$ 425.6	\$ 375.6	\$ 843.3	\$ 751.7
Adjusted diluted earnings per share attributable to SS&C common stockholders	\$ 1.76	\$ 1.49	\$ 3.45	\$ 2.97
GAAP diluted earnings per share attributable to SS&C common stockholders	\$ 0.97	\$ 0.72	\$ 1.88	\$ 1.55
Diluted weighted-average shares outstanding	242.0	252.2	244.6	253.5

- (1) Investment (gains) losses includes unrealized fair value adjustments of investments.
- (2) Other includes additional expenses and income that are permitted to be excluded per the terms of our Credit Agreement from Consolidated EBITDA, a financial measure used in calculating our covenant compliance.
- (3) An estimated effective tax rate of 22.5% has been used to adjust the provision for income taxes for the purpose of computing adjusted net income for the three and six months ended June 30, 2026. An effective tax rate of 22% has been used to retroactively adjust the provision for income taxes for the purpose of computing adjusted net income for the three and six months ended June 30, 2025.
- (4) Adjusted net income attributable to noncontrolling interest represents the proportionate share of adjusted net income of DomaniRx, LLC (a consolidated joint venture) retained by our joint venture partners.